GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bionano Genomics Inc (NAS:BNGO) » Definitions » PE Ratio (TTM)

Bionano Genomics (Bionano Genomics) PE Ratio (TTM) : At Loss (As of Jun. 05, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Bionano Genomics PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-06-05), Bionano Genomics's share price is $0.904. Bionano Genomics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-17.18. Therefore, Bionano Genomics's PE Ratio (TTM) for today is At Loss.


The historical rank and industry rank for Bionano Genomics's PE Ratio (TTM) or its related term are showing as below:

BNGO' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: At Loss   Max: At Loss
Current: At Loss



BNGO's PE Ratio (TTM) is ranked worse than
100% of 400 companies
in the Medical Devices & Instruments industry
Industry Median: 28.615 vs BNGO: At Loss

Bionano Genomics's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.60. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-17.18.

As of today (2024-06-05), Bionano Genomics's share price is $0.904. Bionano Genomics's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-15.35. Therefore, Bionano Genomics's PE Ratio without NRI for today is At Loss.

Bionano Genomics's EPS without NRI for the three months ended in Mar. 2024 was $-0.51. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-15.35.

During the past 3 years, the average EPS without NRI Growth Rate was -8.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 32.30% per year.

During the past 8 years, Bionano Genomics's highest 3-Year average EPS without NRI Growth Rate was 64.50% per year. The lowest was -8.80% per year. And the median was 38.00% per year.

Bionano Genomics's EPS (Basic) for the three months ended in Mar. 2024 was $-0.60. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-17.18.


Bionano Genomics PE Ratio (TTM) Historical Data

The historical data trend for Bionano Genomics's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionano Genomics PE Ratio (TTM) Chart

Bionano Genomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio (TTM)
Get a 7-Day Free Trial At Loss At Loss At Loss At Loss At Loss

Bionano Genomics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Bionano Genomics's PE Ratio (TTM)

For the Medical Instruments & Supplies subindustry, Bionano Genomics's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bionano Genomics's PE Ratio (TTM) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Bionano Genomics's PE Ratio (TTM) falls into.



Bionano Genomics PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Bionano Genomics's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=0.904/-17.180
=At Loss

Bionano Genomics's Share Price of today is $0.904.
Bionano Genomics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.18.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Bionano Genomics  (NAS:BNGO) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Bionano Genomics PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of Bionano Genomics's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Bionano Genomics (Bionano Genomics) Business Description

Traded in Other Exchanges
Address
9540 Towne Centre Drive, Suite 100, San Diego, CA, USA, 92121
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas.
Executives
Gulsen Kama officer: Chief Financial Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Hannah Mamuszka director C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
R. Erik Holmlin director, officer: President and CEO 4088 COMMERCIAL AVE., NORTHBROOK IL 60062
Christopher P. Stewart officer: Chief Financial Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Jonathan V. Dixon officer: General Counsel C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Yvonne Linney director C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
David L Barker director 9885 TOWNE CENTRE DR, SAN DIEGO CA 92121
Aleksandar Rajkovic director 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Vincent Jung-fai Wong director C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Soheil Shams officer: Chief Informatics Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Richard Shippy officer: Chief Business Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Robert J Priar officer: Chief Commercial Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Alka Chaubey officer: Chief Medical Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Heather Adams officer: Chief Administrative Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Kristiina Md Vuori director C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011